文献速递妇科产科

卵巢癌术前分期:超声、CT与全身弥散加权MRI对比(ISAAC研究)

Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole-body diffusion-weighted MRI (ISAAC study).
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

该前瞻性研究纳入67例确诊卵巢癌患者,比较经阴道/经腹超声、增强CT与全身弥散加权MRI在腹膜癌病评估、淋巴结分期及不可切除性预测中的表现。结果显示超声与WB-DWI/MRI在整体腹膜癌病评估上均优于CT(AUC 0.87、0.86 vs 0.77),超声不劣于CT(P=0.002);三种方法在腹膜后淋巴结分期和腹部不可切除性预测上表现相似。

要点

  • 超声与WB-DWI/MRI评估整体腹膜癌病优于CT,超声不劣于CT(P=0.002)。
  • 经阴道超声检测盆腔癌病准确率94%、敏感度94%,高于WB-DWI/MRI和CT。
  • 腹部超声评估肠浆膜及肠系膜准确率70%、敏感度42%,为三种方法最低。

核心结论

  • 在经验丰富的操作者手中,超声可作为WB-DWI/MRI和CT的替代方法用于卵巢癌分期,包括腹膜和淋巴结评估及基于腹部标志物的不可切除性预测。

研究设计与样本

  • 前瞻性研究,2016年3月至2017年10月连续纳入拟在妇科肿瘤中心手术的疑似卵巢癌患者,最终分析67例确诊卵巢癌患者。
  • 术前按单一预设方案行超声、CT和WB-DWI/MRI分期,评估19个腹膜部位和8个淋巴结部位,以手术所见、结局和病理为参考标准。

主要发现

  • 51例(76%)为晚期,16例(24%)为早期卵巢癌。
  • 仅行诊断性腹腔镜者占16%(11/67),开腹者占84%(56/67);术后无残留病灶者占68%(38/56),残留≤1 cm者占16%(9/56),残留>1 cm者占16%(9/56)。
  • 整体腹膜癌病评估AUC:超声0.87、WB-DWI/MRI 0.86、CT 0.77;超声不劣于CT(P=0.002)。
  • 腹膜后淋巴结分期AUC为0.72-0.76,腹部不可切除性预测AUC为0.74-0.80,三种方法表现相似。
  • 经阴道超声检测盆腔癌病准确率94%、敏感度94%,WB-DWI/MRI为91%和91%,CT为85%和89%。

关键数值与推荐

  • 超声在19个腹膜部位的特异度总体高于或等于WB-DWI/MRI和CT,但腹部敏感度较低或相等。
  • 评估直肠乙状结肠壁深部浸润:超声准确率93%、敏感度100%,WB-DWI/MRI为83%和75%,CT为84%和88%。
  • 评估肠浆膜和肠系膜:腹部超声准确率70%、敏感度42%,WB-DWI/MRI为78%和65%,CT为79%和65%。

临床怎么用

  • 在经验丰富的条件下,可考虑将超声作为卵巢癌术前分期的替代或补充手段,尤其用于盆腔癌病和直肠乙状结肠壁浸润评估以规划切除。
  • 腹部肠浆膜和肠系膜评估时超声敏感度较低,需结合WB-DWI/MRI或CT综合判断。

局限性

  • 单中心研究,样本量67例。
  • 超声结果依赖于操作者经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the performance of transvaginal and transabdominal ultrasound with that of the first-line staging method (contrast-enhanced computed tomography (CT)) and a novel technique, whole-body magnetic resonance imaging with diffusion-weighted sequence (WB-DWI/MRI), in the assessment of peritoneal involvement (carcinomatosis), lymph-node staging and prediction of non-resectability in patients with suspected ovarian cancer. METHODS: Between March 2016 and October 2017, all consecutive patients with suspicion of ovarian cancer and surgery planned at a gynecological oncology center underwent preoperative staging and prediction of non-resectability with ultrasound, CT and WB-DWI/MRI. The evaluation followed a single, predefined protocol, assessing peritoneal spread at 19 sites and lymph-node metastasis at eight sites. The prediction of non-resectability was based on abdominal markers. Findings were compared to the reference standard (surgical findings and outcome and histopathological evaluation). RESULTS: Sixty-seven patients with confirmed ovarian cancer were analyzed. Among them, 51 (76%) had advanced-stage and 16 (24%) had early-stage ovarian cancer. Diagnostic laparoscopy only was performed in 16% (11/67) of the cases and laparotomy in 84% (56/67), with no residual disease at the end of surgery in 68% (38/56), residual disease ≤ 1 cm in 16% (9/56) and residual disease > 1 cm in 16% (9/56). Ultrasound and WB-DWI/MRI performed better than did CT in the assessment of overall peritoneal carcinomatosis (area under the receiver-operating-characteristics curve (AUC), 0.87, 0.86 and 0.77, respectively). Ultrasound was not inferior to CT (P = 0.002). For assessment of retroperitoneal lymph-node staging (AUC, 0.72-0.76) and prediction of non-resectability in the abdomen (AUC, 0.74-0.80), all three methods performed similarly. In general, ultrasound had higher or identical specificity to WB-DWI/MRI and CT at each of the 19 peritoneal sites evaluated, but lower or equal sensitivity in the abdomen. Compared with WB-DWI/MRI and CT, transvaginal ultrasound had higher accuracy (94% vs 91% and 85%, respectively) and sensitivity (94% vs 91% and 89%, respectively) in the detection of carcinomatosis in the pelvis. Better accuracy and sensitivity of ultrasound (93% and 100%) than WB-DWI/MRI (83% and 75%) and CT (84% and 88%) in the evaluation of deep rectosigmoid wall infiltration, in particular, supports the potential role of ultrasound in planning rectosigmoid resection. In contrast, for the bowel serosal and mesenterial assessment, abdominal ultrasound had the lowest accuracy (70%, 78% and 79%, respectively) and sensitivity (42%, 65% and 65%, respectively). CONCLUSIONS: This is the first prospective study to document that, in experienced hands, ultrasound may be an alternative to WB-DWI/MRI and CT in ovarian cancer staging, including peritoneal and lymph-node evaluation and prediction of non-resectability based on abdominal markers of non-resectability. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Fischerova D, Pinto P, Burgetova A, et al. Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole-body diffusion-weighted MRI (ISAAC study). Ultrasound Obstet Gynecol. 2022. PMID: 33871110. doi:10.1002/uog.23654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。